Tetrofosmin
Looking up MedlinePlus…
From MedlinePlus, U.S. National Library of Medicine
Dosing in kidney impairment
| Radiation absorbed dose per unit activity injected intravenously | ||||
|---|---|---|---|---|
| Exercise | Rest | |||
| Target organ | rad/mCi | microGy/MBq | rad/mCi | microGy/MBq |
| Gall bladder wall | 0.10 | 27 | 0.13 | 36 |
| Upper large intestine | 0.074 | 20 | 0.10 | 27 |
| Lower large intestine | 0.055 | 15 | 0.074 | 20 |
| Bladder wall | 0.052 | 14 | 0.063 | 17 |
| Small intestine | 0.041 | 11 | 0.056 | 15 |
| Kidney | 0.037 | 10 | 0.048 | 13 |
| Salivary glands | 0.030 | 8.0 | 0.043 | 12 |
| Ovaries | 0.029 | 7.7 | 0.033 | 8.8 |
| Uterus | 0.026 | 7.0 | 0.029 | 7.8 |
| Bone surface | 0.023 | 6.3 | 0.021 | 5.8 |
| Thyroid | 0.017 | 4.7 | 0.020 | 5.5 |
| Pancreas | 0.019 | 5.0 | 0.018 | 4.9 |
| Heart wall | 0.019 | 5.2 | 0.017 | 4.7 |
| Stomach | 0.017 | 4.6 | 0.017 | 4.5 |
| Adrenals | 0.016 | 4.4 | 0.016 | 4.2 |
| Liver | 0.012 | 3.3 | 0.015 | 4.0 |
| Spleen | 0.015 | 4.1 | 0.014 | 3.9 |
| Red marrow | 0.014 | 3.9 | 0.014 | 3.8 |
| Muscle | 0.013 | 3.5 | 0.012 | 3.3 |
| Testes | 0.013 | 3.4 | 0.011 | 3.1 |
| Thymus | 0.012 | 3.3 | 0.010 | 2.8 |
| Esophagus | 0.012 | 3.3 | 0.010 | 2.8 |
| Lungs | 0.012 | 3.2 | 0.010 | 2.8 |
| Brain | 0.010 | 2.7 | 0.0085 | 2.3 |
| Skin | 0.0081 | 2.2 | 0.0074 | 2.0 |
| Breasts | 0.0085 | 2.3 | 0.0074 | 2.0 |
| Remaining organs | 0.014 | 3.8 | 0.014 | 3.8 |
| Effective dose per unit activity | 0.026 rem/mCi | 6.9 microSv/MBq | 0.030 rem/mCi | 8.0 microSv/MBq |
Preparation and administration
Prepare this dose
Your numbers for tetrofosmin. Take vial strength, diluent, and limits from the label below.
Enter a dose to see draw volume, final concentration, and rates.
Administration Instructions Use aseptic technique for all drug preparation and handling. Measure the dose in a suitable radioactivity calibration system immediately prior to intravenous administration. Visually inspect the drug for particulate matter and discoloration prior to administration. Do not use or administer the drug if there is evidence of particulate matter or discoloration.
Instruct patients to remain hydrated and void frequently following administration to decrease radiation exposure [ see Warnings and Precautions ].
Instructions for Preparation The technetium Tc99m labeling reaction involved in the preparation of MYOVIEW Injection depends on maintaining tin in the divalent (reduced) state. Any oxidant present in the sodium pertechnetate Tc99m used may adversely affect the quality of the preparation. Sodium pertechnetate Tc99m containing oxidants should not be used for the preparation of the labeled product.
Elute the technetium generator with sodium chloride injection, USP. Insert a venting needle (standard 18 to 26 gauge needle, not provided) through the rubber septum of the shielded vial containing the lyophilized powder. Inject no more than 89 GBq (
Contraindications
None. None ( 4 )
Safety data
Reported adverse events (FAERS)
Liver injury (LiverTox)
LiverTox has no chapter for tetrofosmin. Check the label's hepatic warnings.
Pregnancy and lactation
Pregnancy
8.1 Pregnancy Risk Summary There are no data with technetium Tc99m tetrafosmin use in pregnant women to inform any drug associated risks. Animal reproduction studies with technetium Tc99m tetrofosmin have not been conducted. However, all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. If considering technetium Tc99m tetrafosmin administration to a pregnant woman advise the pregnant woman of risk to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
For breastfeeding, also see LactMed (National Library of Medicine), which summarizes milk levels and infant effects.
Supply and cost
Drug shortage status
Recalls (last 24 months)
Therapeutic equivalence (Orange Book)
Price ladder
Not the price at the counterThese are not what a patient pays at the pharmacy counter. They are what pharmacies, health plans, and government buyers pay, before manufacturer rebates. A patient's cost depends on their insurance (copay, coinsurance, or deductible) or the pharmacy's cash price.